Table 3 Performance of screening strategies
DAY-1 | Random | DAY-1 + Random | DAY-1 + DAY-2 | DAY-1+ Random + DAY-2 | |
|---|---|---|---|---|---|
Validity Assessments | |||||
True Positive No. | 82 | 79 | 79 | 79 | 77 |
Sensitivity % | 100 | 96.34 | 96.34 | 96.34 | 93.9 |
95%CI | 95.6–100.0 | 89.7–99.2 | 89.7–99.2 | 89.7–99.2 | 86.3–98.0 |
True Negative No. | 52 | 35 | 57 | 58 | 61 |
Specificity % | 69.3 | 46. 7 | 76.0 | 77.3 | 81.3 |
95%CI | 57.6–79.5 | 35.1–58.6 | 64.7–85.1 | 66.2–86.2 | 70.7–89.4 |
False Positive No. | 23 | 40 | 18 | 17 | 14 |
False Positive % | 30.7 | 53.3 | 24.0 | 22.7 | 18.7 |
95%CI | 20.5–42.4 | 41.5–65.0 | 14.9–35.3 | 13.8–33.8 | 10.6–29.3 |
False Negative No. | 0 | 3 | 3 | 3 | 5 |
False Negative % | 0 | 3.66 | 3.66 | 3.66 | 6.1 |
95%CI | 0–4.4 | 0.8–10.3 | 0.8–10.3 | 0.8–10.3 | 2.0–13.7 |
PPV % | 78.1 | 66.4 | 81.4 | 82.3 | 84.6 |
NPV % | 100.0 | 92.1 | 95.0 | 95.1 | 92.4 |
Accuracy % | 85.4 | 72.6 | 86.6 | 87.3 | 87.9 |
Cost-effectiveness Analysis | |||||
Cost (¥) | 5167.42 | 11063.42 | 9035.12 | – | 18652.73 |
Incremental Cost (¥) | 0.00 | 2028.30 | 3867.70 | – | 7589.32 |
Effectiveness (QALYs) | 10.85 | 11.13 | 10.88 | – | 11.87 |
Incremental Effectiveness (QALYs) | 0.00 | 0.25 | 0.03 | – | 0.73 |
ICER (¥/QALYs) | 0.00 | 8134.69 | 112335.88 | – | 10327.99 |